Literature DB >> 33739781

Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification.

Lisa M Rooper1, Prokopios P Argyris, Lester D R Thompson, Jeffrey Gagan, William H Westra, Richard C Jordan, Ioannis G Koutlas, Justin A Bishop.   

Abstract

Mucin-producing salivary adenocarcinomas were historically divided into separate colloid carcinoma, papillary cystadenocarcinoma, and signet ring cell carcinoma diagnoses based on histologic pattern, but have recently been grouped together in the adenocarcinoma not otherwise specified category. It is currently unclear if these tumors represent 1 or more distinct entities and how they are related to well-circumscribed papillary mucinous lesions with recurrent AKT1 E17K mutations that were recently described as salivary intraductal papillary mucinous neoplasm. Here, we sought to evaluate the clinicopathologic and molecular features of salivary mucinous adenocarcinomas to clarify their classification. We identified 17 invasive mucin-producing salivary adenocarcinomas, 10 with a single histologic pattern, and 7 with mixed patterns. While most tumors demonstrated papillary growth (n=15), it was frequently intermixed with colloid (n=6) and signet ring (n=3) architecture with obvious transitions between patterns. All were cytokeratin 7 positive (100%) and cytokeratin 20 negative (0%). Next-generation sequencing performed on a subset demonstrated recurrent AKT1 E17K mutations in 8 cases (100%) and TP53 alterations in 7 cases (88%). Of 12 cases with clinical follow-up (median: 17 mo), 4 developed cervical lymph node metastases, all of which had colloid or signet ring components. Overall, overlapping histologic and immunohistochemical features coupled with recurrent AKT1 E17K mutations across patterns suggests that mucin-producing salivary adenocarcinomas represent a histologically diverse single entity that is closely related to tumors described as salivary intraductal papillary mucinous neoplasm. We propose a unified mucinous adenocarcinoma category subdivided into papillary, colloid, signet ring, and mixed subtypes to facilitate better recognition and classification of these tumors.

Entities:  

Year:  2021        PMID: 33739781     DOI: 10.1097/PAS.0000000000001688

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?

Authors:  Lisa M Rooper; Jeffrey Gagan; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-07-06

Review 2.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: Emerging Entities in Salivary Gland Tumor Pathology.

Authors:  Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-03-21

3.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands.

Authors:  Alena Skálová; Martin D Hyrcza; Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2022-03-21

4.  Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases.

Authors:  Justin A Bishop; Dipti P Sajed; Ilan Weinreb; Brendan C Dickson; Elizabeth A Bilodeau; Abbas Agaimy; Alessandro Franchi; Syed Ali Khurram; Philip Da Forno; Juliana Robledo; John R Kalmar; Sarah Aguirre; Jeffrey F Krane; Jose Luis Tapia; Katalin Kiss; Kitrina Cordell; Molly Rosebush; A William Barrett; Dolphine Oda; Adel Assaad; Toshitaka Nagao; Fumi Kawakami; Masato Nakaguro; Ismail Zahir; Kristina Wakeman; Stephan Ihrler; Jacinthe Chenevert; Yi-Ling Lin; William H Westra; Jeffrey Gagan; Lisa M Rooper
Journal:  Head Neck Pathol       Date:  2021-05-12

5.  SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.

Authors:  Sandra N Freiberger; Muriel Brada; Christine Fritz; Sylvia Höller; Alexander Vogetseder; Milo Horcic; Michel Bihl; Michal Michal; Martin Lanzer; Martin Wartenberg; Urs Borner; Peter K Bode; Martina A Broglie; Tamara Rordorf; Grégoire B Morand; Niels J Rupp
Journal:  Neoplasia       Date:  2021-04-18       Impact factor: 5.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.